Significantly different effects of tetrahydroberberrubine enantiomers on dopamine D1/D2 receptors revealed by experimental study and integrated in silico simulation

Abstract

Tetrahydroberberrubine (TU), an active tetrahydroprotoberberines (THPBs), is gaining increasing popularity as a potential candidate for treatment of anxiety and depression. One of its two enantiomers, l-TU, has been reported to be an antagonist of both D1 and D2 receptors, but the functional activity of the other enantiomer, d-TU, is still unknown. In this study, experiments were combined with in silico molecular simulations to (1) confirm and discover the functional activities of l-TU and d-TU, and (2) systematically evaluate the molecular mechanisms beyond the experimental observations. l-TU proved to be an antagonist of both D1 and D2 receptors (IC 50 = 385 nM and 985 nM, respectively), while d-TU shows no affinity against either D1 or D2 receptor, based on the cAMP assay (D1 receptor) and calcium flux assay (D2 receptor). Results from both flexible-ligand docking studies and molecular dynamic (MD) simulations provided insights at the atomic level. The l-TU-bound structures predicted by MD (1) undergo an outward rotation of the extracellular helical bundles; (2) have an enlarged orthosteric binding pocket; and (3) have a central toggle switch that is prevented from rotating freely. These features are unique to the l-TU enantiomer and provide an explanation for its antagonistic behavior toward both D1 and D2 receptors. The present study provides new sight on the structural and functional relationships of l-TU and d-TU binding to dopamine receptors, and provides guidance to the rational design of novel molecules targeting these two dopamine receptors in the future.

The release of host-derived antibodies bound to the variant surface glycoprotein (VSG) of Trypanosoma brucei cannot be explained by pH-dependent conformational changes of the VSG dimer

“…In our study, sufficient simulation time (200 ns) was applied to observe the protein conformational changes, which could also be used to investigate more complex transmembrane proteins. In particular, the same time-scale protocol was already implemented in various studies to analyse transmembrane dopamine D1/D2 receptors or some multidrug resistance proteins 50 , 51 .…”

Methyleugenol Has an Antidepressant Effect in a Neuroendocrine Model: In Silico and In Vivo Evidence

“…The dopaminergic D1 receptor (PDB ID 7CKW), obtained from the PDB Data Bank, is crystallized with the catechol agonist fenoldopam. According to the literature, the active site of D1 receptor agonists and antagonists act on the same active site, and residues Asp103, Trp 321, Phe 289, Phe 288, Trp 285, Asn 292, and Ser 202 are considered the most influential for antagonist activity at the D1 receptor [47,48].…”

Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson’s Disease Patients

“…In AD, the effective ingredient of berberine hydrochloride berberine has been found to inhibit β / γ -secretion, increase α -secretion, and lessen A β levels in the hippocampus of AD mice, thereby improving cognitive impairment [ 6 ]. In patients with inflammatory bowel disease, berberine has been shown to stimulate dopamine α 2 and α 1 receptors [ 7 ]. The latest study [ 8 ] has confirmed that the striatal dopamine levels were elevated as measured by laser desorption mass spectrometry and berberine enhanced the imaging intensity of brain dopamine in mice receiving oral enterococci.…”